Cambricon, Biwin Storage and 5 other STAR Market leaders collectively disclose operating conditions

Article body EM_StockImg_Start

EM_StockImg_End

In response to market concerns over short-term volatility in the technology sector, several leading companies on the STAR Market have addressed market concerns through announcements. On October 23, seven companies—Cambricon, Biwin Storage, Shengyi Electronics, Yuanjie Semiconductor, Lianxun Instruments, RemeGen, and APT Medical—collectively disclosed their recent production and operating conditions. From AI computing power chips, storage, and high-speed interconnect to innovative drugs and interventional medical devices, these companies demonstrated the resilience of the STAR Market's fundamentals through revenue growth, order reserves, R&D investment, and capacity building.

Among the seven STAR Market companies mentioned above, five come from different segments of the artificial intelligence industry chain. As shown in the announcements, the prosperity signals across the industry chain are not merely at the expectation level: chip companies are seeing rapid revenue and profit growth, PCB, optical chip, and test equipment companies maintain strong order momentum, the demand structure for storage products is accelerating its upgrade, and capacity building and next-generation product validation are advancing in parallel. Demand across the industry chain driven by computing power capital expenditure is gradually translating into the operating results of listed companies. EM_StockImg_End

As a computing power chip company, Cambricon stated that demand in the artificial intelligence computing power market remains robust and can support the company's steady business growth. In the first three quarters of 2026, the company achieved operating revenue of 9.526 billion yuan, up 106.76% year on year; net profit attributable to shareholders of the parent company was 3.715 billion yuan, up 131.49% year on year, an increase of 80.38% over the full year of 2025. Meanwhile, the company's R&D investment in the first three quarters was 1.225 billion yuan, up 45.35% year on year.

In Cambricon's view, as large model technology continues to evolve, the market not only needs more efficient computing hardware to reduce training and inference costs, but also needs more complete software platforms to improve chip usability, scalability, compatibility, and stability in complex scenarios. The company will continue to maintain high-intensity R&D investment in key directions such as chip platforms and software platforms for large models, and strengthen software-hardware collaborative optimization capabilities. EM_StockImg_End

Growing computing power demand is also driving the upgrade of the storage industry. Biwin Storage stated that the company is actively expanding application markets such as emerging AI edge devices, PC and enterprise storage, and smart vehicles, and continues to advance its dual-wheel-driven strategy of "storage + wafer-level advanced packaging and testing," pursuing technology R&D and industrial application in areas such as advanced storage, compute-storage co-packaging, and high-speed optoelectronic interconnect.

The PCB segment is likewise feeling the demand upturn. Shengyi Electronics stated that the company currently has ample orders, a stable supply chain, and a relatively high capacity utilization rate. Thanks to strong demand from downstream sectors such as AI computing power and high-speed communications, the company expects net profit attributable to shareholders of the parent company for the first three quarters of 2026 to be 1.8686 billion yuan to 1.9517 billion yuan, up 68% to 75% year on year. EM_StockImg_End

Shengyi Electronics believes that as AI servers and high-speed switches accelerate their upgrades, high-speed, high-layer PCBs have become key components for ensuring high-speed signal integrity and supporting the stable release of computing power. The company's orders for data center-related products such as AI servers and 800G and 1.6T switches are growing steadily, and its 1.6T optical module products have achieved breakthrough progress.

Capacity release is accelerating, and technology R&D remains vigorous

In the field of high-speed optical communications, Yuanjie Semiconductor and Lianxun Instruments disclosed their latest operating progress from the laser chip and test instrument segments, respectively.

Yuanjie Semiconductor expects to achieve operating revenue of 650 million yuan to 700 million yuan in the third quarter of 2026, up 264.56% to 292.60% year on year; it expects net profit attributable to shareholders of the parent company of 403 million yuan to 453 million yuan, up 578.85% to 659.70% year on year.

In terms of technology and capacity, Yuanjie Semiconductor's multiple products for new packaging technologies such as CPO and NPO are steadily advancing in line with customer demand, and R&D investment in EML and CW products remains vigorous. The civil engineering, part of the cleanrooms, and supporting facilities of Phase II of its optoelectronic communications semiconductor chip and device R&D and production base have been completed, the first batch of production equipment is expected to enter the plant soon, and the project is expected to begin forming capacity between the end of 2026 and early 2027.

Lianxun Instruments stated that downstream customer demand is strong and its order reserves on hand are relatively ample. Core test instruments such as sampling oscilloscopes, bit error rate analyzers, and clock recovery units for testing 800G and 1.6T high-speed optical modules are the company's main products to be delivered in 2026. The company expects net profit attributable to shareholders of the parent company for the first three quarters of 2026 to be 1.9 billion yuan to 2.1 billion yuan, up 1,866.00% to 2,072.95% year on year.

For next-generation speeds, Lianxun Instruments' new-generation sampling oscilloscope and supporting clock recovery unit can meet the eye diagram testing requirements of 2.4T and 3.2T, and the relevant self-developed sample-and-hold chips have been successfully taped out and are planned to be sent to leading industry users for sample validation.

Commercialization of innovative drugs improves in quality and efficiency, and momentum in high-end devices continues to be released

The vitality of technological innovation is also reflected in the fields of biomedicine and high-end medical devices.

RemeGen stated that the commercialization of its core products is advancing steadily and overall operating quality continues to improve. In the first half of 2026, the company achieved operating revenue of 5.853 billion yuan, up 433.11% year on year; net profit attributable to shareholders of the parent company was 4.662 billion yuan, turning from loss to profit year on year; and net cash flow from operating activities was 4.214 billion yuan, further enhancing profit quality and operating resilience.

In terms of internationalization, RemeGen has facilitated global licensing of four core drugs—telitacicept, disitamab vedotin, RC28, and RC148—with cumulative total transaction value exceeding US$12.6 billion. The company stated that it will continue to focus on core therapeutic areas such as autoimmune diseases and oncology, and advance clinical research, commercialization, and global cooperation.

APT Medical is optimistic about the long-term demand for minimally invasive interventional medical devices. The company stated that its current production and operating conditions are good, product market coverage has further improved, and R&D capabilities have continued to strengthen. From 2021 to 2025, the company's operating revenue grew from 829 million yuan to 2.584 billion yuan, with a compound annual growth rate of 32.88%; net profit attributable to shareholders of the parent company grew from 208 million yuan to 821 million yuan, with a compound annual growth rate of 40.95%. In the first half of 2026, the company's operating revenue and net profit attributable to shareholders of the parent company increased by 25.75% and 26.38% year on year, respectively; the growth rates of operating revenue and net profit in the first three quarters increased compared with the first half of the year.

"Looking ahead, APT Medical will continue to increase the coverage rate and hospital penetration rate of vascular interventional products, accelerate the market access of pulsed ablation consumables, and promote the accelerated international market layout of three-dimensional electrophysiology systems, pulsed electric field ablation solutions, and peripheral products," said a relevant person in charge of APT Medical. The company will also continue to advance digital and intelligent upgrades and strengthen technological innovation and commercialization of achievements in fields such as electrophysiology and vascular intervention.

(Source: Dahe Caifang) Body middle embedded advertisement